Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

Throughout her career, One2Treat’s Émilie Barré has focused on developing both the analytical and leadership aspects ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Manas AI secures funding led by General Catalyst to scale AI-driven drug discovery, tackling cancer and rare diseases.

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...

Australian CDMOs, BioCina and NovaCina, have merged in a move to pool their biologic and small molecule production expertise ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

Arctic therapeutics raises funding from EIC Fund, Kaldbakur, and Sanos Group to advance its dementia treatment, AT-001, and acne drug, AT-004. The company aims to transform the treatment landscape for ...

We ran a Q&A with John Clarke, associate director in patient recruitment at Innovaderm on the changing landscape of patient ...

We ran a Q&A With Michael Young, co-founder of Lindus Health on the challenges of 2024 and the company’s goals for 2025.

Advarra conducted a survey of sites, sponsors, and CROs that revealed three biggest barriers to stakeholder collaboration: communications, staffing, and technology.